Bionoid Pharma, Inc.
BINP · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | 4.1% | -64.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | 22.4% | 48.1% | 45.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | $0 | $0 | -$0 |
| % Margin | – | 36% | 5.2% | -78.2% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | $0 | $0 | -$0 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$0 | $0 | $0 | -$0 |
| % Margin | – | 31.3% | 4.1% | -132.2% |
| EPS | -0.005 | -0 | 0 | -0.003 |
| % Growth | -4,900% | – | 100% | – |
| EPS Diluted | -0.005 | -0 | 0 | -0.003 |
| Weighted Avg Shares Out | 54 | 54 | 54 | 43 |
| Weighted Avg Shares Out Dil | 54 | 54 | 54 | 43 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | -$0 | $0 | -$0 |
| % Margin | – | -11.5% | 13.5% | -129.3% |